APA (7th ed.) Citation

Nair, R. R., Sarkar, A., Hariharan, P., Gabrielson, K. L., Wu, T., Liu, C., . . . Sofou, S. (2025). Low-dose temozolomide selectively increases glioblastoma's vascular permeability, tumor microenvironment penetration and the killing potential of systemic actinium-225 α-particle dendrimer-radioconjugates improving treatment efficacy. European Journal of Nuclear Medicine & Molecular Imaging, 52(11), 4308. https://doi.org/10.1007/s00259-025-07332-w

Chicago Style (17th ed.) Citation

Nair, Rajiv Ranjit, et al. "Low-dose Temozolomide Selectively Increases Glioblastoma's Vascular Permeability, Tumor Microenvironment Penetration and the Killing Potential of Systemic Actinium-225 α-particle Dendrimer-radioconjugates Improving Treatment Efficacy." European Journal of Nuclear Medicine & Molecular Imaging 52, no. 11 (2025): 4308. https://doi.org/10.1007/s00259-025-07332-w.

MLA (9th ed.) Citation

Nair, Rajiv Ranjit, et al. "Low-dose Temozolomide Selectively Increases Glioblastoma's Vascular Permeability, Tumor Microenvironment Penetration and the Killing Potential of Systemic Actinium-225 α-particle Dendrimer-radioconjugates Improving Treatment Efficacy." European Journal of Nuclear Medicine & Molecular Imaging, vol. 52, no. 11, 2025, p. 4308, https://doi.org/10.1007/s00259-025-07332-w.